Evolution Equity Partners, a specialist technology investor that focuses on cybersecurity and enterprise software companies, has received a $50.8 million commitment from British Patient Capital for its third fund. This investment follows a previous $35 million commitment to Evolution’s second fund in 2020. The UK’s leadership in cybersecurity innovation and expertise in this valuable technology sector are showcased through this investment.
Robert Greenwood, Investment Director of Funds at British Patient Capital, highlighted the evolution of cybersecurity over the last two decades. He emphasized how it has become a crucial application across all sectors as businesses strive to protect themselves, their customers, and their products. Richard Seewald, Founder and Managing Partner at Evolution Equity Partners, expressed excitement about partnering with British Patient Capital and NSSIF to support UK-based cybersecurity companies. The goal is to provide these companies with capital, knowledge, tools, and strategies to drive performance and success in the global market.
Seewald stressed the critical importance of cybersecurity to the safety of UK-based enterprises, governments, and consumers. He highlighted how the current environment underscores the necessity of next-generation technology that can defend and protect society and our way of life. This investment by British Patient Capital showcases the UK’s commitment to supporting innovative cybersecurity startups and providing them with the resources they need to succeed globally.